3-(Piperidin-4-yl)imidazo[1,5-a]pyridine → HCID 20664162, compound
Reaction equation
[NH:1]1[CH2:6][CH2:5][CH:4]([C:7]2[N:11]3[CH:12]=[CH:13][CH:14]=[CH:15][C:10]3=[CH:9][N:8]=2)[CH2:3][CH2:2]1.[CH:16]([C@@H:18]1[C@@H:22]([C:23]2[CH:28]=[CH:27][CH:26]=[CH:25][CH:24]=2)[CH2:21][N:20]([C@H:29]([CH:42]2[CH2:47][CH2:46][CH2:45][CH2:44][CH2:43]2)[C:30]([O:32]CC2C=CC(OC)=CC=2)=[O:31])[CH2:19]1)=O>>[CH:9]1[N:8]=[C:7]([CH:4]2[CH2:3][CH2:2][N:1]([CH2:16][C@@H:18]3[C@@H:22]([C:23]4[CH:24]=[CH:25][CH:26]=[CH:27][CH:28]=4)[CH2:21][N:20]([C@H:29]([CH:42]4[CH2:47][CH2:46][CH2:45][CH2:44][CH2:43]4)[C:30]([OH:32])=[O:31])[CH2:19]3)[CH2:6][CH2:5]2)[N:11]2[CH:12]=[CH:13][CH:14]=[CH:15][C:10]=12Participants
3
Procedure
The title compound was prepared from 3-(piperidin-4-yl)imidazo[1,5-a]pyridine (from Step B) and 2-(R)-(3-(R)-formyl-4-(S)-phenylpyrrolidin-1-yl)-cyclohexaneacetic acid, (4-methoxy)benzyl ester (Aldehyde 5) using procedures analogous to those described in Example 95 (Steps C and D). ESI-MS 501 (M+1); HPLC A: 1.20 min.
Workup
- custom1.20 min.
Sources & evidence
- ORD record
- ord-822a9159a3b340539c8df97304a0d091
- Source dataset
- uspto-grants-2001_06
- Patent number
- US06248755B1
Reaction notes
Loading…